{"entity":{"id":"ccne1","kind":"target","name":"CCNE1","aka":["cyclin E1","G1/S-specific cyclin-E1"],"tldr":"CCNE1 (G1/S-specific cyclin-E1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.","summary":"Essential for the control of the cell cycle at the G1/S (start) transition.\n\nCIViC holds 16 clinical evidence items and 0 assertions across 3 variants, naming Palbociclib, Dinaciclib, CDK Inhibitor SNS-032 and Camonsertib and others. Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes affected pathway 0.57, literature 0.99, genetic association 0.57, somatic mutation 0.96, animal model 0.64). In OnCo, 1 product record names it (AVZO-021).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:1589","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1589"},{"label":"UniProt P24864","url":"https://www.uniprot.org/uniprotkb/P24864/entry"},{"label":"NCBI Gene 898","url":"https://www.ncbi.nlm.nih.gov/gene/898"},{"label":"Ensembl ENSG00000105173","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105173"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets"],"cancers":["gastric","breast-cancer","ovarian","endometrial","colorectal","urothelial","skin-cancer","breast-hr-positive","gallbladder"],"sections":[],"technologies":[],"targets":[],"drugs":["avzo-021"],"companies":[],"institutions":[],"pathways":["synthetic-lethality-map"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 10 therapies; CIViC holds 16 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Gastric Adenosquamous Carcinoma; Ovarian Serous Cystadenocarcinoma; Endometrial Serous Adenocarcinoma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CCNE1","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:1589","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1589","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P24864","url":"https://www.uniprot.org/uniprotkb/P24864/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CCNE1","url":"https://civicdb.org/features/11","note":"16 evidence items, 0 assertions, 3 variants; diseases: Ovarian Cancer, Breast Cancer, Gastric Adenosquamous Carcinoma, Ovarian Carcinoma, Stomach Cancer and 4 more (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000105173","url":"https://platform.opentargets.org/target/ENSG00000105173/associations","note":"association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: colorectal cancer 0.58, gastric cancer 0.51, urinary bladder cancer 0.52, skin cancer 0.50, breast cancer 0.50 (GraphQL API, CC0)"}],"specificity":"tumour-associated","distribution":"many-types","specificityNote":"Tumour-associated overexpression: HPA finds the RNA tissue enhanced in normal bone marrow, placenta, so the tumour and the normal tissue it comes from share the target and the medicine relies on the difference in level. HPA CCNE1: RNA tissue enhanced (bone marrow 34 nTPM, placenta 29 nTPM); high antibody staining in 4 normal tissues; highest cancer staining carcinoid (1 of 4 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Biliary tract cancer (all types), Gastric & gastro-oesophageal junction cancer, Breast cancer (all types), Ovarian cancer, Endometrial cancer, Colorectal cancer, Bladder & urothelial cancer and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas CCNE1 tissue","url":"https://www.proteinatlas.org/ENSG00000105173-CCNE1/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas CCNE1 pathology","url":"https://www.proteinatlas.org/ENSG00000105173-CCNE1/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000105173 associations","url":"https://platform.opentargets.org/target/ENSG00000105173/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:1589","ensembl":"ENSG00000105173","uniprot":"P24864","entrez":"898","firstDescribed":1991,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Lew D.J. et al, Cell, 1991, \"Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/1833066/","biology":"Essential for the control of the cell cycle at the G1/S (start) transition. Location: Nucleus (UniProt). Locus 19q12 (HGNC).","whereFound":["Gastric & gastro-oesophageal junction cancer: Open Targets association 0.51 with gastric cancer (MONDO_0001056); CIViC evidence names this disease","Breast cancer: Open Targets association 0.50 with breast cancer (MONDO_0007254); CIViC evidence names this disease","Ovarian cancer: CIViC evidence names this disease","Endometrial cancer: CIViC evidence names this disease","Colorectal cancer: Open Targets association 0.58 with colorectal cancer (MONDO_0005575)","Bladder & urothelial cancer: Open Targets association 0.52 with urinary bladder cancer (MONDO_0001187)","Gallbladder cancer: amplification about 9%"],"targetClass":"other","prevalence":[{"cancerId":"gallbladder","pct":9,"measure":"Amplification","source":"https://www.cbioportal.org/study/summary?id=gbc_mskcc_2022","note":"Amplification in 22 of 244 samples, 9.0%, in cBioPortal gbc_mskcc_2022."}]},"route":"/targets/ccne1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"drug":[{"id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/"}],"pathway":[{"id":"synthetic-lethality-map","kind":"pathway","name":"Synthetic lethality: paired dependencies","route":"/pathways/synthetic-lethality-map/"}]}}